Showing 61 - 80 results of 39,013 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (nn decrease)) ))', query time: 0.94s Refine Results
  1. 61
  2. 62
  3. 63
  4. 64
  5. 65
  6. 66
  7. 67

    Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A by Yasuko Kato (122938)

    Published 2012
    “…The numbers of all three types of cells were significantly decreased by the 8<sup>th</sup> week of naris occlusion (<b>C</b>, red bars, <i>n</i> = 4) compared with the control group (<b>C</b>, blue bars, <i>n</i> = 5). …”
  8. 68
  9. 69

    Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses by Jing Wang (6206297)

    Published 2025
    “…However, how global land use changes impact soil N supply and potential N loss remains elusive. By compiling a global data set of 1,782 paired observations from 185 publications, we show that land use conversion from natural to managed ecosystems significantly reduced NNM by 7.5% (−11.5, −2.8%) and increased NN by 150% (86, 194%), indicating decreasing N availability while increasing potential N loss through denitrification and nitrate leaching. …”
  10. 70

    The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

    Published 2019
    “…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”
  11. 71
  12. 72
  13. 73
  14. 74
  15. 75
  16. 76

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
  17. 77

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  18. 78
  19. 79
  20. 80

    Time allocation may not decrease with price for a non-linear microscopic utility of leisure. by Ritwik K. Niyogi (427932)

    Published 2014
    “…Consequently, <i>TA</i> no longer decreases but may even increase with price (A, lower panel). …”